Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Dr. Tiago Reis Marques, Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference as follows:


GlobeNewswire Inc | Sep 29, 2021 04:30PM EDT

September 29, 2021

MIAMI BEACH, Fla., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Dr. Tiago Reis Marques, Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference as follows:

Date: Thursday, September 30, 2021Time: 10:10AM ETWebcast Link: https://www.benzinga.com/events/small-cap/healthcare/

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Companys website at www.pasithea.com, under the Investors section.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Its biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability.

The Companys secondary operations focus on providing business support services to anti-depression clinics in the United Kingdom and in the United States. The Companys operations in the United Kingdom will involve providing business support services to registered healthcare providers who will assess patients, and if appropriate, administer intravenous infusions of ketamine, and the Companys operations in the United States will involve providing business support services to entities that furnish similar services.

Pasithea Therapeutics Corp. Company ContactDr. Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com

Pasithea Therapeutics Corp. Investor RelationsLisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC